Most cancer deaths are attributable to the metastatic phase of the disease. However, the molecular and cellular mechanisms that allow tumor cells to leave the primary site, survive during transit through the blood and establish and maintain a new tumor in a secondary organ remain poorly understood. Using a genetically engineered mouse model of metastatic non-small cell lung cancer in which primary tumors can be unambiguously linked to their metastases, we will systematically and comprehensively characterize alterations at the genetic, gene expression, and epigenetic levels. The model utilizes conditional mutations in the K-Ras oncogene and the p53 tumor suppressor gene, which are both mutated at high frequency in human lung cancer. These studies will employ cutting-edge methods in molecular genetic analysis, relying extensively on next generation DNA sequencing technology. In addition, we will use transposon-mediated mutagenesis system to perform a forward genetic screen to identify genes that enhance metastatic behavior. Data from these studies will be subjected to integrative bioinformatic analysis to increase the ability to identify metastasis pathways, including performing cross-species analysis with data from human lung cancer specimens. Candidate genes and pathways will be validated in large series of tumors and metastases from the mouse model as well as in human lung cancer patient samples. We will probe the biological function of candidate metastasis genes and pathways using a combination of cell-based and in vivo approaches, including altering gene function in the autochthonous model. The information gained from these studies is expected to provide new insights into the biological basis of metastasis in mouse models and in human lung cancer. An improved understanding of these processes has the potential to improve diagnosis of aggressive lung cancer, lead to treatments that target metastatic lesions as well as methods to inhibit metastatic spread. Given that an estimated 1.4 million individuals will succumb to lung cancer in the United States and throughout the world over the next year, most of them from the consequences of metastasis, new insights into lung cancer metastasis are highly relevant to human health.

Public Health Relevance

Lung cancer is the leading cause of cancer death in the United States, with approximately 175,000 lung cancer patients dying each year. Despite an increasingly sophisticated understanding of the molecular events that accompany lung tumor development in humans, this has not as yet translated into more effective means to treat or control the disease. Most cancer patients die of complications resulting from the growth of metastases. Cancer survival will be greatly impacted by enhanced understanding of the underlying metastasis biology and through development of both new therapies and improved diagnosis/prediction of prognosis.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRLB-Q (M1))
Program Officer
Marks, Cheryl L
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Massachusetts Institute of Technology
Internal Medicine/Medicine
Schools of Arts and Sciences
United States
Zip Code
Li, Carman Man-Chung; Gocheva, Vasilena; Oudin, Madeleine J et al. (2015) Foxa2 and Cdx2 cooperate with Nkx2-1 to inhibit lung adenocarcinoma metastasis. Genes Dev 29:1850-62
Li, Carman Man-Chung; Chen, Guoan; Dayton, Talya L et al. (2013) Differential Tks5 isoform expression contributes to metastatic invasion of lung adenocarcinoma. Genes Dev 27:1557-67
Snyder, Eric L; Watanabe, Hideo; Magendantz, Margaret et al. (2013) Nkx2-1 represses a latent gastric differentiation program in lung adenocarcinoma. Mol Cell 50:185-99
Winslow, Monte M; Dayton, Talya L; Verhaak, Roel G W et al. (2011) Suppression of lung adenocarcinoma progression by Nkx2-1. Nature 473:101-4
Young, Nathan P; Crowley, Denise; Jacks, Tyler (2011) Uncoupling cancer mutations reveals critical timing of p53 loss in sarcomagenesis. Cancer Res 71:4040-7
Shaw, Alice T; Winslow, Monte M; Magendantz, Margaret et al. (2011) Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress. Proc Natl Acad Sci U S A 108:8773-8
Kirsch, David G; Grimm, Jan; Guimaraes, Alexander R et al. (2010) Imaging primary lung cancers in mice to study radiation biology. Int J Radiat Oncol Biol Phys 76:973-7
Young, Nathan P; Jacks, Tyler (2010) Tissue-specific p19Arf regulation dictates the response to oncogenic K-ras. Proc Natl Acad Sci U S A 107:10184-9
Oliver, Trudy G; Mercer, Kim L; Sayles, Leanne C et al. (2010) Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. Genes Dev 24:837-52
DuPage, Michel; Dooley, Alison L; Jacks, Tyler (2009) Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat Protoc 4:1064-72

Showing the most recent 10 out of 20 publications